RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study

This article was originally published here

The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and

The post RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply